CoChat

A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice

Open access
Merlin, Simone, Cannizzo, Elvira Stefania, Borroni, Ester, Bruscaggin, Valentina, Schinco, Piercarla, Tulalamba, Warut, Chuah, Marinee K., Arruda, Valder R., VandenDriessche, Thierry, Prat, Maria, Valente, Guido, Follenzi, Antonia · 2017 · Molecular Therapy
Cited by 59

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Hemophilia A (HA) is an X-linked bleeding disease caused by factor VIII (FVIII) deficiency. We previously demonstrated that FVIII is produced specifically in liver sinusoid endothelial cells (LSECs) and to some degree in myeloid cells, and thus, in the present work, we seek to restrict the expression of FVIII transgene to these cells using cell-specific promoters. With this approach, we aim to limit immune response in a mouse model by lentiviral vector (LV)-mediated gene therapy encoding FVIII. To increase the target specificity of FVIII expression, we included miRNA target sequences (miRTs) (i.e., miRT-142.3p, miRT-126, and miRT-122) to silence expression in hematopoietic cells, endothelial cells, and hepatocytes, respectively. Notably, we report, for the first time, therapeutic levels of FVIII transgene expression at its natural site of production, which occurred without the formation of neutralizing antibodies (inhibitors). Moreover, inhibitors were eradicated in FVIII pre-immune mice through a regulatory T cell-dependent mechanism. In conclusion, targeting FVIII expression to LSECs and myeloid cells by using LVs with cell-specific promoter minimized off-target expression and immune responses. Therefore, at least for some transgenes, expression at the physiologic site of synthesis can enhance efficacy and safety, resulting in long-term correction of genetic diseases such as HA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2017.04.029

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 59

Metadata

Authors
Merlin, S., Cannizzo, E. S., Borroni, E., Bruscaggin, V., Schinco, P., Tulalamba, W., Chuah, M. K., Arruda, V. R., VandenDriessche, T., Prat, M., Valente, G., & Follenzi, A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2017-08
Volume
25
Issue
8
Pages
1815-1830
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2610928572
Cited by
59
References
14
FWCI
6.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. https://app.cochat.ai/papers/10.1016/j.ymthe.2017.04.029
The paper
Merlin, S., Cannizzo, E. S., Borroni, E., Bruscaggin, V., Schinco, P., Tulalamba, W., Chuah, M. K., Arruda, V. R., VandenDriessche, T., Prat, M., Valente, G., & Follenzi, A. (2017). A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.04.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.